Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial
Erin J Campbell, Amanda Norman, Yvonne Bonomo, Andrew J Lawrence
BRAIN RESEARCH | ELSEVIER | Published : 2020
Alcohol use disorder (AUD) is a complex neuropsychiatric disease state in which currently approved pharmacotherapeutics are of relatively low effect at a population level. One reason for this may be that current pharmacotherapeutics focus on the reward pathway in relapse prevention, rather than addressing AUD from a holistic perspective. Importantly, one often overlooked symptom of AUD is sleep disruption. In recent years, an efficient, relatively low risk and economic strategy that has proven successful in other disorders is the repositioning or repurposing of drugs approved for the treatment of other indications. Suvorexant, a dual orexin receptor antagonist, has been licensed for the trea..View full abstract
Awarded by NHMRC
This work is supported by a Perpetual IMPACT philanthropic grant to AJL and EJC via the Percy Baxter Charitable Trust and a Victoria Medical Research Acceleration Fund 2 grant from the Victorian State Government. AJL is a NHMRC Principal Fellow (1116930) and we acknowledge the Victorian State Government Operational Infrastructure Scheme. Suvorexant and matched placebo tablets are provided gratis by Merck.